Contact the Editorial Desk

Editorial correspondence

The desk welcomes notes on the record itself: a citation quoted imprecisely, a newer trial that should replace or sit alongside an older one, a regulatory status that has changed, or a peer-reviewed study on BPC-157, semaglutide, thymosin alpha-1, CJC-1295 or MOTS-c that belongs on the references page. Corrections that make a page more accurate or more current are the most useful messages this desk receives.

The easiest notes to act on name three things: which page, the exact passage in question, and the supporting source — a DOI or PubMed identifier wherever available. In that shape, a proposed correction can be checked against its source before anything is changed.

Editorial mailbox: editors@definitivepeptides.com

What this desk cannot help with

Because this site reports and cites the research literature rather than practicing medicine or selling anything, it cannot:

• Advise on or recommend human use of any peptide covered here.
• Name a dose, schedule, or route for any individual.
• Judge whether a finding from a cited study applies to a specific person's situation.
• Source, sell, or point toward a supplier for any compound.
• Substitute for guidance from a licensed clinician.

Semaglutide is an approved prescription medicine; thymosin alpha-1 is approved abroad as thymalfasin but not in the United States; BPC-157, CJC-1295 and MOTS-c are unapproved research chemicals. Anyone with a medical question should bring it to a licensed clinician in their own jurisdiction. Replies to editorial correspondence are not guaranteed and may take time.